journal article·2022-02-09

Nanoscale Force-Mapping-Based Quantification of Low-Abundance Methylated DNA

Woo Cheol Shim, Sungwook Woo, Joon Won Park

Nano Letters· Volume 22· Issue 3
Publisher page

Abstract

Methylation changes at cytosine–guanine dinucleotide (CpG) sites in genes are closely related to cancer development. Thus, detection and quantification of low-abundance methylated DNA is critical for early diagnosis. Here, we report an atomic force microscopy (AFM)-based quantification method for DNA that contains methyl-CpG at a specific site, without any treatment to the target DNA such as chemical labeling, fluorescence tagging, or amplification. We employed AFM-tip-tethered methyl-CpG-binding proteins to probe surface-captured methylated DNA. We observed a linear correlation (R2 = 0.982) between the input copy number and detected copy number, in the low copy number regime (10 or fewer; subattomolar concentrations). For a mixture of methylated and nonmethylated DNA that resembles clinical samples, we were still able to quantify the methylated DNA. These results highlight the potential of our force-mapping-based quantification method for wide applications in early detection of diseases associated with methylated DNA.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Genomics and Chromatin Dynamics · RNA modifications and cancer · RNA and protein synthesis mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Pohang University of Science and Technology, 77 Cheongam-Ro, Nam-Gu, Pohang 37673, Republic of Korea

Institute of Convergence Science, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea

Funding

National Research Foundation of Korea

References (62)

Show source-provided references
1. 10.1016/j.ctrv.2011.04.01010.1016/j.ctrv.2011.04.010 ↗
2. 10.1038/3504755410.1038/35047554 ↗
3. 10.1038/nn.266610.1038/nn.2666 ↗
4. 10.1016/j.molcel.2018.08.00810.1016/j.molcel.2018.08.008 ↗
5. 10.1038/sj.onc.120565110.1038/sj.onc.1205651 ↗
6. 10.2217/epi.09.3310.2217/epi.09.33 ↗
7. Wang D. · Am. J. Cancer Res. · 2014 · 4 · 725
8. 10.1002/ijc.3152610.1002/ijc.31526 ↗
9. 10.1016/j.bbrc.2007.07.05110.1016/j.bbrc.2007.07.051 ↗
10. 10.1186/s12885-018-4706-x10.1186/s12885-018-4706-x ↗
11. 10.1016/j.jgg.2018.02.00710.1016/j.jgg.2018.02.007 ↗
12. 10.3390/cancers1204078910.3390/cancers12040789 ↗
13. 10.1073/pnas.89.5.182710.1073/pnas.89.5.1827 ↗
14. 10.1073/pnas.93.18.982110.1073/pnas.93.18.9821 ↗
15. 10.1093/nar/gkn69110.1093/nar/gkn691 ↗
16. 10.1093/nar/gkl113410.1093/nar/gkl1134 ↗
17. 10.1038/251636a010.1038/251636a0 ↗
18. 10.1038/ng159810.1038/ng1598 ↗
19. 10.1021/ja060681j10.1021/ja060681j ↗
20. 10.1158/0008-5472.CAN-06-188810.1158/0008-5472.CAN-06-1888 ↗
21. 10.1016/0022-2836(78)90242-510.1016/0022-2836(78)90242-5 ↗
22. 10.1016/0022-2836(78)90243-710.1016/0022-2836(78)90243-7 ↗
23. 10.1038/327336a010.1038/327336a0 ↗
24. 10.1039/C7AY00232G10.1039/C7AY00232G ↗
25. 10.1080/15592294.2015.106849010.1080/15592294.2015.1068490 ↗
26. 10.1038/nbt.155910.1038/nbt.1559 ↗
27. 10.1007/s00216-015-8458-z10.1007/s00216-015-8458-z ↗
28. 10.1186/1471-2105-15-28310.1186/1471-2105-15-283 ↗
29. 10.1038/s41598-018-27368-310.1038/s41598-018-27368-3 ↗
30. 10.3390/jcm907228310.3390/jcm9072283 ↗
31. 10.1126/science.793966010.1126/science.7939660 ↗
32. 10.1038/nmeth87110.1038/nmeth871 ↗
33. 10.1038/nmeth.347910.1038/nmeth.3479 ↗
34. 10.1073/pnas.070035110410.1073/pnas.0700351104 ↗
35. 10.1038/nature0862610.1038/nature08626 ↗
36. 10.1038/nmat142810.1038/nmat1428 ↗
37. 10.1038/7892910.1038/78929 ↗
38. 10.1038/s41586-021-03551-x10.1038/s41586-021-03551-x ↗
39. 10.1038/nature0945010.1038/nature09450 ↗
40. 10.1093/nar/gkr57810.1093/nar/gkr578 ↗
41. 10.1038/nnano.2010.21210.1038/nnano.2010.212 ↗
42. 10.1016/j.aca.2020.05.02910.1016/j.aca.2020.05.029 ↗
43. QI Mode–Quantitative Imaging with the NanoWizard 3 AFM; JPK BioAFM, Bruker Nano GmbH: Berlin, Germany. https://www.jpk.com/app-technotes-img/AFM/pdf/jpk-tech-quantitative-imaging.14-1.pdf (accessed on 2021–11–29).
44. 10.1021/jacs.6b0504810.1021/jacs.6b05048 ↗
45. 10.1016/j.micron.2013.02.00310.1016/j.micron.2013.02.003 ↗
46. 10.2217/epi.15.3910.2217/epi.15.39 ↗
47. 10.1039/C6ME00073H10.1039/C6ME00073H ↗
48. 10.1093/protein/gzv04610.1093/protein/gzv046 ↗
49. Only one residue discrepancy out of 69: threonine versus alanine, at equivalent residue positions of the fragment; at residues 200 of MBD2(h) and 203 of MBD2(m) when counted from the N-terminus of the whole proteins, respectively.
50. UniProt Sequence Information (MBD2_human). https://www.uniprot.org/uniprot/Q9UBB5 (accessed 2021–11–29).
51. UniProt Sequence Information (MBD2_mouse). https://www.uniprot.org/uniprot/Q9Z2E1 (accessed 2021–11–29).
52. 10.5772/3609010.5772/36090 ↗
53. 10.1093/nar/gkg24910.1093/nar/gkg249 ↗
54. 10.1021/la046951y10.1021/la046951y ↗
55. 10.1021/ja067610510.1021/ja0676105 ↗
56. The force detection proportion values were much higher in the reference study, because the mentioned study included all single force events in the counting process unlike our approach of including only positive (count 2 or 3) pixels. (If we also take all single force events into consideration, as if we had taken just one measurement for each pixel as in the reference study, then the force detection proportion values become ∼8.2% and ∼2.3%, giving a ratio of ∼3.6.) In addition to the dissimilar counting schemes, differences in sample treatment protocols may have caused differences in surface immobilization density and force measurement efficiency, among other factors, which would have collectively affected the counts.
57. 10.1021/ac303784810.1021/ac3037848 ↗
58. 10.1186/1471-2407-13-14210.1186/1471-2407-13-142 ↗
59. 10.2147/OTT.S22342310.2147/OTT.S223423 ↗
60. 10.1021/jacs.6b0279110.1021/jacs.6b02791 ↗
61. 10.1021/acs.analchem.8b0335010.1021/acs.analchem.8b03350 ↗
62. 10.1093/nar/gni08710.1093/nar/gni087 ↗